Pfizer’s 20-Valent Vaccine And Prevnar Successor Succeeds In Phase III

 
• By Mandy Jackson
  
microscope
Pfizer's 20vPnC was non-inferior to its Prevnar 13 vaccine
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D